Modulation of adaptive immunity

Modulation of adaptive immunity refers to the therapeutic alteration of the immune system's specialized, antigen-specific responses mediated by T and B lymphocytes. Unlike the innate immune system, the adaptive system provides highly specific recognition of pathogens and the development of immunological memory (Janeway et al., Immunobiology, 2001). Therapeutic strategies in this area include immunosuppression to treat autoimmune diseases and prevent organ transplant rejection, as well as immunostimulation to enhance anti-tumor activity or vaccine efficacy (Abbas et al., Cellular and Molecular Immunology, 2021). Common molecular targets within this process include immune checkpoints like PD-1 and CTLA-4, as well as various cytokines and their receptors. Because 'Modulation of adaptive immunity' describes a broad physiological outcome or therapeutic goal rather than a single molecular entity, it is not considered a specific drug target in a biochemical sense. Instead, it serves as a functional classification for a wide range of interventions that impact the body's long-term immune defenses.

Other names

Adaptive immune modulationImmune system modulationRegulation of adaptive immune response

Not applicable as this is a biological process; drugs targeting this process act via specific molecular targets such as checkpoint receptors, cytokines, or signaling kinases to either stimulate or suppress T-cell and B-cell activity.